Core Viewpoint - The Shanghai Titan Technology Co., Ltd. is preparing for its 2024 Annual General Meeting (AGM) to discuss various proposals, including financial institution credit applications and stock issuance to specific targets, while ensuring shareholder rights and meeting legal requirements [1][2][3]. Group 1: Meeting Procedures - The AGM will verify the identity of attendees and restrict entry to authorized personnel only [2][3]. - Attendees must sign in 30 minutes before the meeting and present necessary identification [2][3]. - The meeting will follow a predetermined agenda for discussing and voting on proposals [2][3][4]. Group 2: Proposals Overview - Proposal 1: Approval of the 2024 Annual Report and its summary [7]. - Proposal 2: Approval of the 2024 Board of Directors' Work Report [9]. - Proposal 3: Approval of the 2024 Supervisory Board's Work Report [10]. - Proposal 4: Approval of the 2024 Financial Settlement Report [11]. - Proposal 5: Approval of the 2024 Profit Distribution Plan, proposing a cash dividend totaling 11,510,588.39 yuan, which is 89.28% of the net profit [11][12]. - Proposal 6: Approval of the 2025 Expected Daily Related Transactions [13][14]. - Proposal 7: Renewal of the accounting firm for the 2025 financial audit [15]. - Proposal 8: Approval of the 2024 Impairment Provision [16][17][18]. - Proposal 9: Approval for the company and its subsidiaries to apply for a total credit limit of up to 4.195 billion yuan from financial institutions [21][22][23]. - Proposal 10: Approval of the 2025 Director Compensation Plan [26]. - Proposal 11: Approval of the 2025 Supervisor Compensation Plan [27]. - Proposal 12: Authorization for the Board to issue stock to specific targets up to 300 million yuan [28]. Group 3: Financial Performance - The company reported a revenue of 288,352.06 million yuan for 2024, a year-on-year increase of 4.11%, while the net profit decreased by 82.23% to 12,892,914.72 yuan due to competitive pricing strategies [29][30]. - The company maintained a stable R&D investment of 15,775.81 million yuan, representing 5.47% of revenue, and filed for 61 new patents [31].

上海泰坦科技股份有限公司 2024 年年度股东大会会议资料 上海泰坦科技股份有限公司 2024年年度股东大会会议资料 股票代码：688133 股票简称：泰坦科技 2025 年 5 月 第1页 上海泰坦科技股份有限公司 2024 年年度股东大会会议资料 | 2024 | 年年度股东大会会议须知 | 3 | | | --- | --- | --- | --- | | 2024 | 年年度股东大会会议议程 | 5 | | | 2024 | 年年度股东大会会议议案 | 7 | | | 议案一 | 《关于公司<2024 | 年年度报告全文及其摘要>的议案》 7 | | | 议案二 | 《关于公司<2024 | 年度董事会工作报告>的议案》 8 | | | 议案三 | 《关于公司<2024 | 年度监事会工作报告>的议案》 9 | | | 议案四 | 《关于公司<2024 | 年度财务决算报告>的议案》 | 10 | | 议案五 | 《关于公司<2024 | 年年度利润分配预案>的议案》 | 11 | | 议案六 | 《关于公司<2025 | 年度日常关联交易预计>的议案》 | 13 | | 议案七 | 《关于续聘会计师 ...

近期泰坦科技(688133)发布2025年一季报，证券之星财报模型分析如下： 泰坦科技2025年一季度财务表现 收入与利润 债务情况 公司有息负债为14.87亿元，同比增长18.59%，有息资产负债率为30.66%，显示出一定的债务风险。此 外，近3年的经营性现金流均为负数，意味着公司可能面临较大的资金压力。 总结 总体来看，泰坦科技在2025年一季度实现了盈利能力的显著提升，但同时也面临着现金流紧张和债务水 平较高的挑战。投资者应密切关注公司未来的现金流管理和债务偿还能力。 泰坦科技在2025年一季度实现营业总收入6.04亿元，较去年同期下降9.07%。然而，公司的归母净利润 达到512.98万元，同比大幅上升122.27%；扣非净利润为227.99万元，同比增长8.86%。这表明公司在控 制成本和提高效率方面取得了一定成效。 盈利能力 本报告期内，泰坦科技的毛利率为23.25%，同比增加了11.79个百分点；净利率为0.31%，同比增幅达 85.62%。这些数据显示出公司盈利能力有所增强。 费用控制 尽管如此，公司的销售费用、管理费用及财务费用总计达到9710.53万元，占营业收入的比例为 16.08%， ...

证券代码：688133 证券简称：泰坦科技 公告编号：2025-021 上海泰坦科技股份有限公司 第四届监事会第十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况： 上海泰坦科技股份有限公司（以下简称"公司"）第四届监事会第十四次会 议通知已于 2025 年 4 月 25 日以书面方式送达全体监事，会议于 2025 年 4 月 29 日在上海市徐汇区石龙路 89 号会议室以现场结合通讯方式召开，本次会议由监 事会主席顾梁先生召集并主持，应到监事 3 人，实到监事 3 人。本次会议的召集 和召开符合《中华人民共和国公司法》和《上海泰坦科技股份有限公司章程》等 相关规定，会议形成的决议合法、有效。 二、监事会会议审议情况： 与会监事就如下议案进行了审议，并表决通过以下事项： 1、审议通过《关于<公司 2025 年第一季度报告>的议案》 根据《公司法》、《证券法》等相关法律法规、《公司章程》等内部规章的 规定及《上海证券交易所科创板股票上市规则》，公司编制了 2025 年第一季度 报告。 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥603,969,457.66, a decrease of 9.07% compared to the same period last year[4]. - Net profit attributable to shareholders increased by 122.27% to ¥5,129,765.53, driven by improved operational quality and government subsidies[4][8]. - Basic and diluted earnings per share rose by 50% to ¥0.03 per share[4][8]. - The company reported a net profit margin of approximately 0.28% for Q1 2025, down from 0.07% in Q1 2024[19]. - The net profit for Q1 2025 was CNY 1,855,610.93, an increase of 68.7% compared to CNY 1,099,310.93 in Q1 2024[20]. - The total comprehensive income for Q1 2025 was CNY 1,767,308.38, compared to CNY 1,203,726.29 in Q1 2024, reflecting a growth of 47%[21]. - Operating profit for Q1 2025 was CNY 2,392,234.71, a decrease of 18.8% from CNY 2,946,193.53 in Q1 2024[20]. Expenses and Costs - Research and development expenses totaled ¥37,871,158.33, accounting for 6.27% of operating revenue, an increase of 0.39 percentage points year-on-year[5]. - Total operating costs for Q1 2025 were RMB 601,897,479.15, down 9.05% from RMB 661,767,508.11 in Q1 2024[19]. - Operating costs included RMB 463,552,791.02 in cost of goods sold for Q1 2025, a decrease of 12.00% from RMB 526,100,925.06 in Q1 2024[19]. - The company incurred financial expenses of CNY 9,577,527.23 in Q1 2025, an increase of 35.5% from CNY 7,069,593.39 in Q1 2024[20]. - The company reported a decrease in sales expenses to CNY 45,226,581.01 in Q1 2025, down 15.5% from CNY 53,433,412.88 in Q1 2024[20]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥4,851,268,756.45, reflecting a slight increase of 0.05% from the end of the previous year[5]. - Current assets totaled RMB 3,084,338,957.65 as of March 31, 2025, a slight decrease from RMB 3,138,932,782.27 at the end of 2024[15]. - Non-current assets amounted to RMB 1,766,929,798.80 as of March 31, 2025, an increase from RMB 1,709,744,921.17 at the end of 2024[16]. - Total liabilities were RMB 1,977,261,780.79 as of March 31, 2025, slightly down from RMB 1,977,971,310.67 at the end of 2024[17]. - Shareholders' equity totaled RMB 2,874,006,975.66 as of March 31, 2025, compared to RMB 2,870,706,392.77 at the end of 2024[17]. Cash Flow - The net cash flow from operating activities was negative at -¥108,861,607.63, an improvement from -¥135,326,803.12 in the same period last year[4]. - The company reported a cash flow from operating activities net amount of CNY -108,861,607.63 for Q1 2025, an improvement from CNY -135,326,803.12 in Q1 2024[24]. - The company’s investment activities generated a net cash flow of CNY -77,092,006.71 in Q1 2025, an improvement from CNY -136,666,844.65 in Q1 2024[24]. - The cash and cash equivalents at the end of Q1 2025 were CNY 823,797,571.09, down from CNY 935,563,412.14 at the end of Q1 2024[25]. Strategic Focus - The company is focusing on enhancing profitability by prioritizing profit over scale, leading to a reduction in low-margin businesses[8]. - The company plans to focus on market expansion and new product development in the upcoming quarters[13]. Shareholder Information - The total number of shareholders and their respective holdings were disclosed, with the top shareholder holding 9.88% of the shares[9][11]. Return on Equity - The weighted average return on equity improved to 0.18%, up by 0.10 percentage points compared to the previous year[4]. Non-Recurring Items - Non-recurring gains and losses amounted to ¥2,849,890.74, primarily due to government subsidies and other factors[6][7].

| 名称 | 持有数量(万股) | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 谢应波 | 1623.94 | 9.88 | 不变 | | 张庆 | 754.12 | 4.59 | 不变 | | 张华 | 754.00 | 4.59 | 不变 | | 王靖宇 | 753.93 | 4.58 | 不变 | | 许峰源 | 753.53 | 4.58 | 不变 | | 上海高毅资产管理合伙企业(有限合伙)-高毅邻山1号远望基 金 | 600.00 | 3.65 | 不变 | | 苏州钟鼎五号股权投资基金合伙企业(有限合伙) | 463.20 | 2.82 | 不变 | | 上海创丰昕汇创业投资管理有限公司-天津创丰昕华创业投 | | | | | 资合伙企业(有限合伙) | 375.88 | 2.29 | 不变 | | 中信证券股份有限公司-社保基金17052组合 | 274.31 | 1.67 | 不变 | | 上海科技创业投资股份有限公司 | 238.88 | 1.45 | 不变 | 三、分红送配方案情况 | 报告期指标 | 20 ...

Group 1: Urgency in Major Projects - The construction of major projects in Fengxian New Town is driven by a sense of urgency, focusing on timely investment and commencement to address both corporate investment efficiency and local community needs [1][2] - The renovation of Dingfeng Soy Sauce Factory, which began in January 2022, is set to open in May 2023, enhancing public amenities and providing 295 parking spaces [2] - The new Xinhua Hospital branch in Fengxian, with a bed count of 4.77 per thousand people, is expected to alleviate local healthcare challenges, with trial operations starting on June 28 [2] Group 2: Long-term Industry Development - The "Oriental Beauty Valley" initiative, proposed in 2015, has seen significant growth, with the Titan Technology Life Science Headquarters being a new focal point for the health industry [3] - The life sciences sector requires a long-term commitment, with support for research teams through funding and resources to shorten project development cycles [3] - The area has attracted leading companies in cosmetics and biomedicine, with a brand value exceeding 33.8 billion and an industry scale nearing 100 billion [3] Group 3: Strategic Planning and Development - The Digital Jiang Hai Phase I Park is a key project in Fengxian New Town, emphasizing careful planning due to the higher costs associated with "industrial building" projects [4] - The park's design requires meticulous consideration of infrastructure such as lifting points and ventilation systems, reflecting a deep understanding of industrial development patterns [4]

Financial Performance - The company's operating revenue for 2024 was CNY 2,883,520,638.14, representing a 4.11% increase compared to CNY 2,769,649,016.88 in 2023[22]. - The net profit attributable to shareholders for 2024 was CNY 12,892,914.72, a significant decrease of 82.23% from CNY 72,571,508.67 in 2023[22]. - The net profit after deducting non-recurring gains and losses was CNY 5,720,909.40, down 88.87% from CNY 51,386,347.86 in the previous year[22]. - The company's cash flow from operating activities turned positive, reaching CNY 189,009,610.70, a substantial improvement from a negative cash flow of CNY -124,528,370.14 in 2023[23]. - The total assets increased by 10.49% to CNY 4,848,677,703.44 in 2024, compared to CNY 4,388,324,960.93 in 2023[23]. - Basic earnings per share decreased by 87.10% to CNY 0.08 in 2024, down from CNY 0.62 in 2023[24]. - The company's operating costs increased by 5.43% to 2,302,369.88 million RMB, slightly outpacing revenue growth, leading to a decrease in gross margin[128]. - Financial expenses surged by 64.38% to 35,192.77 million RMB due to increased short-term and long-term borrowings[128]. - The company reported a significant increase in goodwill by 51.50% to CNY 152,619,463.82 due to the acquisition of three new companies[150]. Research and Development - The R&D expenditure as a percentage of operating revenue was 5.47% in 2024, slightly down from 5.68% in 2023[24]. - Research and development expenses rose by 4.63% to 147,623.26 million RMB, reflecting the company's commitment to enhancing new product development capabilities[128]. - The company applied for 61 new patents and software copyrights during the reporting period, obtaining 34, bringing the total to 310, including 73 invention patents[61]. - The company has not formed new core technologies during the reporting period but has increased investment in product-related technologies, focusing on synthetic reagents, biological reagents, high-purity solvents, and small instruments[59]. - The company is committed to investing in new product development and technology to drive future growth[186]. Market Strategy and Expansion - The company is focusing on expanding its market share in key product lines and enhancing collaboration with major clients[34]. - The company aims to enhance its competitive advantage by continuously developing high-quality, unique products through increased R&D investment[55]. - The company intends to actively expand overseas channels to establish a foundation for its proprietary brand products in international markets[174]. - The company is considering strategic acquisitions to bolster its market position, with a focus on companies that complement its existing product offerings[187]. - The company plans to pursue mergers and acquisitions during the industry's consolidation phase to enrich its proprietary brand product line and enhance competitiveness[171]. Corporate Governance - The company has received a standard unqualified audit report from Da Xin Accounting Firm[5]. - The company has confirmed that all board members attended the board meeting[5]. - The company has not reported any significant changes in its registered address or office location[15]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - The company has not experienced any violations of decision-making procedures regarding external guarantees[8]. - The company has established specialized committees, including an audit committee and a strategic committee, to enhance governance[199]. Risk Management - The company has outlined potential risks in its annual report, which investors should be aware of[7]. - The company faces risks related to procurement delays and the need for diverse product offerings to maintain user experience and reputation[120]. - The company is at risk of core technology leakage due to reliance on OEM manufacturers for production, which could impact its competitive advantage[119]. - The company has improved its operational efficiency, reducing the delivery cost per order by approximately 7.32%[36]. Product Development and Innovation - The company has developed a flow chemistry technology that enhances reaction efficiency and safety, allowing for continuous production with a small footprint of 5 square meters[56]. - The project aims to optimize reaction processes in microchannel technology, addressing issues related to fluid transport, heat transfer, and mass transfer for large-scale production[69]. - The project has established a high-throughput screening platform for drug discovery and development, focusing on antiviral and anticancer new drugs[70]. - The company is focusing on the development of environmentally friendly and safe synthesis methods for its products[79]. - The project has developed over 10 types of fluorinated key drug building blocks with a purity exceeding 98%[83]. Financial Management - The company plans to implement a capital increase through retained earnings, with a projected profit distribution of 70.76% for the financial director[185]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 572.55 million RMB[193]. - The company has restricted assets totaling 509,914,964.16 RMB, which includes cash of 3,878,692.96 RMB, intangible assets of 15,402,237.50 RMB, fixed assets of 154,677,054.70 RMB, and construction in progress of 335,956,979.00 RMB[153]. - The company plans to use part of the idle raised funds for cash management and has proposed to extend some fundraising projects[198]. Shareholder Engagement - The company held a total of 3 shareholder meetings in 2024, ensuring compliance with regulations and allowing all shareholders to exercise their voting rights[178]. - The board of directors convened 6 meetings in 2024, reviewing and approving the annual report and other matters[179]. - The independent director Jiang Wengong resigned due to personal work commitments during the reporting period[194]. - The independent director Luo Shoujian was elected as a replacement independent director[194].

二、董事会对独立董事独立性情况的评估意见 经深入核查,独立董事胡颖女士、骆守俭先生、朱正刚先生的任职经历以 及相关自查文件,确认上述人员未在公司担任除独立董事以外的任何职务,也 未在公司主要股东公司担任任何职务,与公司以及公司主要股东之间不存在利 害关系或其他可能妨碍其进行独立客观判断的关系。 公司独立董事在 2024 年度始终保持高度的独立性,其履职行为符合《上市 公司独立董事管理办法》《上海证券交易所科创板股票上市规则》《上海证券交 易所科创板上市公司自律监管指引第 1 号 -- 规范运作》等法律法规要求及 《公司章程》等规章制度中关于独立董事独立性的严格规定和要求,有效履行 了独立董事职责,为董事会决策提供了公正、独立的专业意见,有效发挥了参与 决策、监督制衡、专业咨询作用。 上海泰坦科 2025 年 上海泰坦科技股份有限公司 董事会对独立董事独立性自查情况的专项报告 一、独立董事独立性自查情况 上海泰坦科技股份有限公司(以下简称"公司")现有独立董事3人,分别 为胡颖女士、骆守俭先生、朱正刚先生。根据《上市公司独立董事管理办法》 《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律 ...

证券代码：688133 证券简称：泰坦科技 公告编号：2025-016 上海泰坦科技股份有限公司 关于 2024 年度计提减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、计提减值准备情况概述 为客观、公允地反映上海泰坦科技股份有限公司（以下简称"公司"）截至 2024 年 12 月 31 日的财务状况及 2024 年度的经营成果，本着谨慎性原则，根据 《企业会计准则》及公司会计政策、会计估计的相关规定，公司对截至 2024 年 12 月 31 日公司及子公司的应收票据、应收账款、其他应收款、存货、合同资产 等进行了减值测试，并根据减值测试的结果相应计提了减值准备。 2024 年度，公司计提资产减值损失和信用减值损失共计人民币 2,294.37 万 元，具体情况如下： 合同资产的减值准备计提参照预期信用损失的确定方法。在每个资产负债表 日评估相关金融工具的信用风险自初始确认后是否显著增加。经测试，公司 2024 年度计提合同资产减值损失 0.02 万元。 （二）信用减值损失 本公司以预期信用损失为基础，对 ...